NeuroOne Medical Technologies Files Definitive Additional Materials
Ticker: NMTC · Form: DEFA14A · Filed: Feb 7, 2025 · CIK: 1500198
| Field | Detail |
|---|---|
| Company | Neuroone Medical Technologies CORP (NMTC) |
| Form Type | DEFA14A |
| Filed Date | Feb 7, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, filing-update, medical-devices
TL;DR
NeuroOne Medical files more proxy docs, shareholders get more info.
AI Summary
NeuroOne Medical Technologies Corporation filed a Definitive Additional Materials filing (DEFA14A) on February 7, 2025. This filing relates to their proxy statement and is not a preliminary proxy statement. The company is located in Eden Prairie, MN, and operates in the surgical and medical instruments sector.
Why It Matters
This filing indicates that NeuroOne Medical Technologies is providing further information to shareholders regarding their proxy statement, which is crucial for upcoming shareholder votes and corporate governance decisions.
Risk Assessment
Risk Level: low — This filing is a routine administrative document related to proxy statements and does not inherently present new financial or operational risks.
Key Players & Entities
- NEUROONE MEDICAL TECHNOLOGIES Corp (company) — Registrant
- 0001500198 (company) — Central Index Key
- 270863354 (company) — IRS Number
- DE (company) — State of Incorporation
- 0930 (company) — Fiscal Year End
- 001-40439 (company) — SEC File Number
- 25601663 (company) — Film Number
- 7599 ANAGRAM DR (company) — Business Address Street 1
- EDEN PRAIRIE (company) — Business Address City
- MN (company) — Business Address State
FAQ
What type of filing is this DEFA14A for NeuroOne Medical Technologies?
This is a Definitive Additional Materials filing, as indicated by the form type and the checkmark next to 'Definitive Additional Materials'.
When was this filing submitted to the SEC?
The filing was submitted on February 7, 2025.
What is NeuroOne Medical Technologies Corporation's primary business sector?
NeuroOne Medical Technologies Corporation operates in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' sector, with SIC code 3841.
Where is NeuroOne Medical Technologies Corporation headquartered?
The company's business address is located at 7599 Anagram Dr, Eden Prairie, MN 55344.
Was a fee required for this filing?
No fee was required for this filing, as indicated by the checkmark next to 'No fee required'.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 15.8 · Accepted 2025-02-07 16:05:04
Filing Documents
- ea0230318-defa14a_neuroone.htm (DEFA14A) — 12KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-011304.txt ( ) — 18KB
From the Filing
ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant   Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 NeuroOne Medical Technologies Corporation (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. NeuroOne Medical Technologies Corporation 7599 Anagram Dr. Eden Prairie, MN 55344 SUPPLEMENT TO THE PROXY STATEMENT DATED JANUARY 21, 2025 FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD FEBRUARY 14, 2025 This Second Supplement (this “Supplement”), dated February 7, 2025, further supplements the definitive proxy statement on Schedule 14A (the “Proxy Company, with the U.S. Securities and Exchange Commission (the “SEC”) on January 21, 2025, as supplemented on February 5, 2025, in connection with the solicitation by the Company’s Board of Directors (the “Board”), of proxies to be voted at the 2025 Annual Meeting of Stockholders, or any adjournment or postponement thereof (the “Annual Meeting”). We are providing this Supplement to correct the description of what constitutes a quorum for the Annual Meeting. As such, the disclosure included on page 1 of the Proxy “The holders of one-third of the outstanding shares of stock entitled to vote at the Annual Meeting as of the record date must be present, in person or by proxy duly authorized at the Annual Meeting in order to hold the Annual Meeting and conduct business. This presence is called a quorum. Your shares are counted as present at the Annual Meeting if you are present and vote in person at the Annual Meeting or if you have properly submitted a proxy.” THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT, WHICH CONTAINS IMPORTANT ADDITIONAL INFORMATION. Except as to the matters specifically discussed herein, this Supplement does not otherwise modify or update any information or disclosure contained in the Proxy Statement. Capitalized terms used but not otherwise defined in this Supplement shall have the meanings assigned to such terms in the Proxy Statement.